Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for acute T-cell-mediated rejection after kidney transplantation
2013-002825-52Phase 2Completed
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in kidney allograft rejection, sponsored by Medizinische Hochschule Hannover. Primary endpoint: Regression of infiltrate in graft biopsy. Started Dec 2013; status: completed.
02
Drugs
canakinumab
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2013-002825-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002825-52.